Am J Transplant, Volume 18, Suppl 3 Archives - Page 145 of 211 - ATC Abstracts

2018 American Transplant Congress
Performance of Molecular Diagnostic Algorithms of T-Cell Mediated Kidney Rejection (TCMR) in Non-Transplant Biopsies with Interstitial Nephritis
Z. Wang,¹ P. Liu,² G. Tseng,² G. Zeng,¹ P. Randhawa.¹
¹Transplant Pathology, Thomas E Starzl Transplant Institute, University of Pittsburgh, School of Medicine, Pittsburgh, PA; ²Epidemiology, Graduate School of Public Health, and University of Pittsburgh, Pittsburgh, PA.
DNA microarray based tools for the diagnosis of TCMR have been developed and are now being offered commercially. There is need to further evaluate the…
2018 American Transplant Congress
Receiving Hypertensive Donor Has an Inferior Prognosis in Simultaneous Liver Kidney Transplantation Recipient
Z. Guo, Z. Zhu, S. Huang, Y. Tang, Z. Zhang, X. He, G. Chen.
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Background: The impacts of hypertensive (HTN) donor on the prognosis of simultaneous liver kidney transplantation (SLKT) patient are not known to date, and an applicable…
2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
B-.G. Na, E. Lee, S. Kim, S. Park.
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…
2018 American Transplant Congress
Living Liver Donation is Safe in Donors Heterozygous for an alpha-1 Antitrypsin Gene Mutation
T. Bittermann,¹ L. Wood,² P. Abt,² A. Shaked,² K. Olthoff,² D. Goldberg.^1,3
¹Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA; ²Division of Transplant Surgery, University of Pennsylvania, Philadelphia, PA; ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Patients homozygous for an alpha-1 antitrypsin mutation, particularly the Pi*ZZ phenotype, develop cirrhosis and pulmonary emphysema. Those with a heterozygous phenotype are thought to have…
2018 American Transplant Congress
The Grade of Pre-Transplant Portal Vein Thrombosis in Liver Transplant Recipients Impacts Graft and Patient Survival
M. Safwan, M. Sobolic, S. Nagai, R. Schilke, K. Collins, A. Yoshida, M. Abouljoud, M. Rizzari.
Henry Ford Transplant Institute, Henry Ford Health System, Detroit, MI.
Background: Portal vein thrombosis (PVT) in the pre-transplant (pretx) setting makes liver transplantation technically challenging and is also known to affect post transplant outcomes. Few…
2018 American Transplant Congress
Outcomes of Donation after Cardiac Death Liver Grafts from Donors ≥ 50 Years of Age: A Multi-Center Analysis
K. P. Croome,¹ A. K. Mathur,³ D. D. Lee,¹ A. A. Moss,³ C. B. Rosen,² J. K. Heimbach,² C. B. Taner.¹
¹Mayo Clinic Florida, Jacksonville, FL; ²Mayo Clinic Rochester, Rochester, MN; ³Mayo Clinic Arizona, Scottsdale, AZ.
Introduction:As the population in the United States continues to age, an increase in the number of potential DCD donors with advanced chronological age can be…
2018 American Transplant Congress
De Novo Belatacept in Clinical Vascularized Composite Allotransplantation
L. C. Cendales,¹ D. S. Ruch,² A. R. Cardones,³ G. Potter,⁴ J. Dooley,⁵ D. Dore,⁶ J. Orr,¹ G. Ruskin,⁶ M. Song,¹ D. Chen,⁷ A. Selim,⁷ A. D. Kirk.¹
¹Surgery, Duke University, Durham, NC; ²Orthopedics, Duke University, Durham, NC; ³Dermatology, Duke University, Durham, NC; ⁴Psychiatry and Behavioral Sciences, Duke University, Durham, NC; ⁵Anesthesiology, Duke University, Durham, NC; ⁶Psysical and Occupational Therapy, Duke University, Durham, NC; ⁷Pathology, Duke University, Durham, NC.
Most immunosuppressive regimens in vascularized composite allotransplantation (VCA) have been calcineurin inhibitor (CNI)–based. Costimulation blockade has emerged as a replacement for CNI–based regimens in kidney…
2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
J. Gottlieb, C. Neurohr, J. Müller-Quernheim, H. Wirtz, B. Sill, H. Wilkens, V. Besa, C. Knosalla, M. Junge, C. Capusan, M. Strüber.
Klinik, Hannover, Germany; Klinik, München, Germany; Klinik, Freiburg, Germany; Klinik, Leipzig, Germany; Klinik, Hamburg, Germany; Klinik, Homburg, Germany; Klinik, Essen, Germany; Klinik, Berlin, Germany; Novartis Pharma, Nürnberg, Germany; Novartis Pharma, Nürnberg, Germany; Klinik, Hannover, Germany.
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…
2018 American Transplant Congress
Anti-Angiotensin II Type 1-Receptor Antibodies (AT1R-Ab) Induce a Specific Phenotype of Rejection Distinct from HLA Antibody-Mediated Rejection
C. Lefaucheur,¹ D. Viglietti,¹ O. Aubert,¹ A. Philippe,² P. Halloran,³ A. Loupy,¹ D. Dragun.²
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²Medical Faculty of the Charité, Berlin, Germany; ³Alberta Transplant Applied Genomics Centre, Edmonton, Canada.
AT1R-Ab have been associated with kidney allograft rejection; however, their ability to induce a specific rejection phenotype, independent of HLA-DSAs, has not been defined.In a…
2018 American Transplant Congress
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies
F. Shihab,¹ Y. Qazi,^1,2 V. Peddi,¹ D. Shaffer,¹ D. Kim,^1,2 K. McCague,³ D. Patel,³ S. Mulgaonkar.^1,2
¹US92 Study Group, Salt Lake City; ²TRANSFORM Study Group, East Hanover; ³Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…